Compare Amgen, Inc. (AMGN) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Oscar Health Inc — how do they compare? Amgen, Inc. trades at $417.2 (market cap $224.14B), while Oscar Health Inc trades at $29.49 (market cap $8.63B). The key difference: Amgen, Inc. is far larger — about 26× Oscar Health Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| AMGN | OSCR | |
|---|---|---|
Market Cap | $224.14B | $8.63B |
Sector | Health | Health |
52-Week High | $417.20 | $32.18 |
52-Week Low | $271.18 | $10.85 |
Enterprise Value | $267.45B | $4.99B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
Oscar Health (OSCR) trades at $29.11, up 5.2% with strong recent earnings momentum, beating estimates in Q1 and Q2 2026. The stock shows bearish technical signals but benefits from record profitability and raised 2026 guidance. Revenue surged 70% to $4.9 billion in H1 2026, with net income turning positive at $551 million versus a 2025 loss. Valuation remains attractive with P/S of 0.53, suggesting potential undervaluation versus sector peers.
Outlook is positive given membership growth and cost discipline, but risks include medical cost volatility and competitive pressures. Analyst consensus price target of $32.50 implies 12% upside, though technical resistance near $30 may limit near-term gains. Execution on guidance and sustained margin expansion are key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
